Clinical Trials Logo

Filter by:
NCT ID: NCT02868632 Withdrawn - Pancreatic Cancer Clinical Trials

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Start date: August 7, 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, three-cohort, phase Ib study to determine the safety, recommended phase 2 dose (RP2D), and efficacy of Stereotactic Body Radiation Therapy (SBRT) in combination with either (A) MEDI4736 alone, (B) tremelimumab alone, or (C) the combination of MEDI4736 and tremelimumab for patients with unresectable locally advanced adenocarcinoma of pancreas.

NCT ID: NCT02866084 Withdrawn - Headache Clinical Trials

Neuromodulation Treatment of Vestibular Migraines

Start date: September 28, 2016
Phase: N/A
Study type: Interventional

This is a non-randomized pilot study to test the efficacy of neuromodulation via caloric stimulation on vestibular migraines. All subject who meet the study criteria will be in an active treatment group. All subjects will report the frequency of the migraines and undergo periodic testing of symptoms.

NCT ID: NCT02863822 Withdrawn - Dyspepsia Clinical Trials

Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.

Start date: September 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet in functional dyspepsia (FD). The investigators will compare education in the low FODMAP diet to a standard healthy diet for improving symptoms in FD.

NCT ID: NCT02863458 Withdrawn - Clinical trials for Acute Myeloid Leukemia

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

Start date: September 1, 2018
Phase:
Study type: Observational [Patient Registry]

The study aims to comprehensively analyze data from a large and unselected older AML population in the US, both treated and untreated. These data will widen understanding of treatment decisions for the older Acute Myeloid Leukemia (AML) population. Through use of the SEER-Medicare Registry, the effectiveness and impact of HMA treatments as well as the effectiveness of lenalidomide will be studied.

NCT ID: NCT02863042 Withdrawn - Ankle Fracture Clinical Trials

Is Deltoid Ligament Repair for Ankle Fracture Necessary?

AnkleFX
Start date: May 2016
Phase: N/A
Study type: Interventional

The investigator hypothesizes that primary acute ankle deltoid ligament repair can help restore ankle radiographic congruity and functional outcomes.

NCT ID: NCT02862184 Withdrawn - Clinical trials for Female Sexual Dysfunction

Female Sexual Dysfunction, Risks and Outcomes (FSFI)

FSFI
Start date: July 2016
Phase: N/A
Study type: Observational

Many women will likely experience a sexual problem in their lifetimes. The Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking (PRESIDE) study surveyed more than 30,000 U.S. women aged >18 years regarding sexual function. Results from this study estimated that 12% of women experience a diagnosable sexual disorder that causes personal distress, with lack of sexual desire being the most prevalent. - See more at: http://www.uspharmacist.com/content/d/featured_articles/c/56908/#sthash.LTDkyRlR.dpuf

NCT ID: NCT02861612 Withdrawn - Clinical trials for Spinal Cord Injuries

Nerve Transfers to Restore Hand Function in Spinal Cord Injury

Start date: August 2016
Phase:
Study type: Observational

This study seeks to evaluate the efficacy of nerve transfers in restoring hand function in patients with cervical spinal injuries.

NCT ID: NCT02861040 Withdrawn - Clinical trials for Recurrent Adult Acute Lymphoblastic Leukemia

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: August 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this investigational research study is to determine how safe and tolerable the study drug volasertib is in combination with liposomal vincristine (Marqibo; an FDA-approved drug) in patients with relapsed/refractory acute lymphoblastic leukemia. While VSLI demonstrated an overall response rate of 35% in Acute Lymphoblastic Leukemia (ALL) patients that had failed to respond to or relapsed after chemotherapy, combining it with other agents may increase clinical benefit. Volasertib inhibits proteins involved in the cell cycle that are increased in ALL. When volasertib inhibits these proteins ALL cells die. In the laboratory, volasertib has been shown to increase activity of vincristine against ALL cells. Therefore, we think the combination of volasertib and VSLI will be more effective against your leukemia than either drug used alone. This study will try to find out what effects, good and/or bad, this drug combination has on the patient and their cancer, and to find a dose that may be used in future studies.

NCT ID: NCT02860897 Withdrawn - Surgery Clinical Trials

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

Start date: July 2016
Phase: Phase 4
Study type: Interventional

PURPOSE: To evaluate patient adherence to cream versus tablet based local estrogen therapy by randomizing treatment modalities to determine differences in adherence to either form. HYPOTHESIS: There is no difference in adherence to cream versus tablet based local estrogen therapy when prescribed as a 6 week course of postoperative therapy after female pelvic reconstructive surgery.

NCT ID: NCT02860065 Withdrawn - Alzheimer's Disease Clinical Trials

CPC-201 Alzheimer's Disease Type Dementia: PET Study

Start date: September 30, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effect of low and high dose CPC-201 on brain function including cerebral acetylcholinesterase (AChE) activity measured by positron emission tomography (PET).